Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva Gains First Generic Zofran Injection Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA approval comes roughly one month ahead of patent expiration for GSK's injectable antiemetic.

You may also be interested in...



Par Launches Generic Zofran ODT Following FDA Clearance

The agency also clears Dr. Reddy’s immediate-release ondansetron formulation which the Indian firm said it will launch shortly.

Par Launches Generic Zofran ODT Following FDA Clearance

The agency also clears Dr. Reddy’s immediate-release ondansetron formulation which the Indian firm said it will launch shortly.

Zofran Patent Ruling

Two method-of-use patents for GlaxoSmithKline's Zofran are valid and infringed by Teva's ANDA, Wilmington, Del. federal Judge Gregory Sleet ruled Aug. 20

Topics

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel